CellaVision AB (publ)
CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology la… Read more
CellaVision AB (publ) (CLVSF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.058x
Based on the latest financial reports, CellaVision AB (publ) (CLVSF) has a cash flow conversion efficiency ratio of 0.058x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($51.43 Million) by net assets ($887.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CellaVision AB (publ) - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how CellaVision AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CellaVision AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CellaVision AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enjoyor
SHE:300020
|
0.013x |
|
Dingli Communications Corp Ltd
SHE:300050
|
-0.011x |
|
MEC Company Ltd.
PINK:MECGF
|
N/A |
|
Kangxin New Materials Co Ltd
SHG:600076
|
-0.008x |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
0.039x |
|
Fine Organic Industries Limited
NSE:FINEORG
|
0.066x |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
0.029x |
|
Jiangsu Hanvo Safety Product Co. Ltd.
SHE:300952
|
0.027x |
Annual Cash Flow Conversion Efficiency for CellaVision AB (publ) (2007–2025)
The table below shows the annual cash flow conversion efficiency of CellaVision AB (publ) from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $887.58 Million | $200.53 Million | 0.226x | -6.99% |
| 2024-12-31 | $816.89 Million | $198.44 Million | 0.243x | -11.41% |
| 2023-12-31 | $716.39 Million | $196.44 Million | 0.274x | +28.15% |
| 2022-12-31 | $641.63 Million | $137.28 Million | 0.214x | -27.22% |
| 2021-12-31 | $543.28 Million | $159.72 Million | 0.294x | +77.58% |
| 2020-12-31 | $429.62 Million | $71.12 Million | 0.166x | -54.22% |
| 2019-12-31 | $348.37 Million | $125.99 Million | 0.362x | +41.78% |
| 2018-12-31 | $290.38 Million | $74.07 Million | 0.255x | -30.10% |
| 2017-12-31 | $240.85 Million | $87.90 Million | 0.365x | -1.73% |
| 2016-12-31 | $206.18 Million | $76.57 Million | 0.371x | -22.55% |
| 2015-12-31 | $183.52 Million | $88.00 Million | 0.480x | +82.35% |
| 2014-12-31 | $151.30 Million | $39.78 Million | 0.263x | +27.77% |
| 2013-12-31 | $132.52 Million | $27.27 Million | 0.206x | +123.68% |
| 2012-12-31 | $124.91 Million | $11.49 Million | 0.092x | -63.77% |
| 2011-12-31 | $126.07 Million | $32.02 Million | 0.254x | +151.39% |
| 2010-12-31 | $113.42 Million | $11.46 Million | 0.101x | -63.28% |
| 2009-12-31 | $74.80 Million | $20.58 Million | 0.275x | +896.24% |
| 2008-12-31 | $45.98 Million | $1.27 Million | 0.028x | -91.68% |
| 2007-12-31 | $20.07 Million | $6.67 Million | 0.332x | -- |